If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
336
results.
Updated on
20/08/2026 [07:44:00]
Results 150 to 175 of 336
Absstract of: WO2026153209A1
A biosensing element. The biosensing element comprises: a substrate, and a thin film transistor and a reaction chamber which are located on one side of the substrate. The thin film transistor comprises: a gate, a gate insulating layer, an active layer, a source and a drain which are stacked. The thin film transistor is located in the reaction chamber, and antibodies are provided in the reaction chamber. The thin film transistor further comprises a protective layer including at least one of a first protective layer and a second protective layer, wherein the first protective layer is located between the gate insulating layer and the active layer, the second protective layer comprises a first portion that is located on the side of the part of the active layer exposed by the source and the drain away from the substrate, and a water contact angle of a material of the protective layer is greater than that of a material of the gate insulating layer.
Absstract of: WO2025120152A1
The present invention relates to antibodies or binding fragments thereof for use in methods of identifying or diagnosing diseases associated with extracellular trap formation or release from cells, such as Neutrophil Extracellular Trap (NET)-associated pathologies or Eosinophil Extracellular Trap (EET) -associated pathologies.
Absstract of: US20260201041A1
0000 The present invention relates to anti-CD103 antibodies, as well as use of these antibodies in diagnosis, prognosis, monitoring, and treatment of diseases.
Absstract of: US20260202374A1
The present disclosure provides a method of manufacturing a biosensor for detecting a biomarker of Alzheimer's disease, comprising steps of depositing an aluminum oxide film on a Si substrate by an atomic layer deposition system to form an Al2O3/Si substrate; depositing electrical contacts Cr/Au on the Al2O3/Si substrate by a thermal evaporator to form a source, a drain and a planar gate on the Al2O3/Si substrate; providing a bilayer graphene on the Al2O3/Si substrate by thermal annealing under a vacuum environment; providing a bilayer graphene to a low-damage plasma treatment (LDPT) with a mixture of oxygen and hydrogen to form a graphene oxide/graphene (GO/G) layered composite on the Al2O3/Si substrate; and immobilizing an antibody on a surface of the GO/G layered composite through a reaction between amine groups of the antibody and carboxyl groups of GO of the GO/G layered composites, wherein the antibody is specific for p-tau217 protein.
Absstract of: AU2024418168A1
A protein antigen for Alzheimer's disease detection comprises at least any two of DOC2A, LGALS1, KDM4D, and ADARB1 proteins at the same time, can be used for early detection or diagnosis of Alzheimer's disease, and is suitable for risk assessment and prediction of before the onset of Alzheimer's disease; moreover, the protein antigen can distinguish Alzheimer's disease from other types of dementia, and can be further prepared into a related reagent or kit according to requirements.
Absstract of: US20260201023A1
0000 Provided herein are antibodies, or fragments thereof, that specifically bind to a microtubule-binding region (MTBR) of tau, and uses thereof. Further provided are methods of detecting species of MTBR in blood or cerebral spinal fluid, and the use of such detection for diagnosing, prognosing, or staging pathological features and/or clinical symptoms of tauopathies, and to choose treatments appropriate for a given disease stage.
Absstract of: WO2025014769A1
The present application provides, in some aspects, methods of assaying for β-catenin depots, and uses thereof, such as to identify a compound that modulates, such as increases, the β-catenin depots in a cell. In other aspects, also provided herein are associated methods (such as methods of identifying a compound useful for treating a β-catenin associated disease), kits, and useful compounds identified therefrom.
Absstract of: US20260202426A1
0000 The present disclosure relates to a method of detecting a molecule associated with the diagnosis of a disease through movement of the molecules after fluorescent labeling or by using dynamic X-rays. A method of detecting a molecule associated with the diagnosis of a disease through movement of the molecules after fluorescent labeling or labeling with a crystalline plane, according to an aspect, enables large-scale imaging and Z-axis imaging, and thus can be effectively used in the field of diagnosis.
Absstract of: AU2024395871A1
The present disclosure provides methods for simultaneously identifying dynamic and disease-associated RNA binding protein (RBP)-RNA interaction (PRI) sites at single nucleotide resolution across the entire transcriptome. The methods disclosed herein recapitulates PRI profiles obtained with several distinct conventional PRI methods in a single assay at efficiencies that are improved by orders of magnitude, and permit the identification of the specific RBP bound at a PRI.
Absstract of: US20260201046A1
Provided is a heterohybridoma-based method of generating recombinant rabbit monoclonal antibodies, recombinant anti-IL-6 receptor-alpha (IL-6Rα) antibodies generated using such methods, and immune assay methods kits employing such antibodies.
Absstract of: AU2024388350A1
The disclosure features anti-tumor necrosis factor receptor superfamily (TNFRSF), anti-tumor necrosis factor superfamily (TNFSF), anti-CD28, and anti-ICOS antibodies and antigen-binding fragments thereof with amino acid modifications at the Fc domain, and the use of these antibodies or antigen-binding fragments to modulate immune response. The antibodies and antigen-binding fragments thereof can be used to treat a wide variety of cancers, autoimmune disorders, neurological disorders, infectious diseases, inflammatory diseases, and transplant rejections.
Absstract of: US20260202397A1
0000 The present invention describes a method for assessing the potency of a pharmaceutical product assumed to be effective in treating a disorder, preferably a genetic disorder or a non-genetic disorder, wherein the disorder results in an impaired functionality of a physiological bodily function of a subject having the disorder, wherein the method comprises: (i) incubating an engineered tissue with the pharmaceutical product, wherein the engineered tissue is or has been modified to be representative for the disorder; (ii) determining at least one physical parameter of the engineered tissue resulting from step (i), wherein the physical parameter is a measure of the functionality of the physiological bodily function, and (iii) determining whether a value of the at least one physical parameter determined in step (ii) meets a predetermined threshold of said physical parameter, which determines whether the pharmaceutical product has potency, wherein, if said value of the at least one physical parameter exceeds the predetermined threshold, potency of the pharmaceutical product is indicated for treating the disorder by at least partially restoring the functionality of the physiological bodily function.
Absstract of: US20260200988A1
Polypeptides capable of specifically recognizing and binding to the neutral amino acid transporter ASCT1/SLC1A4, while not binding to the related neutral amino acid transporter ASCT2/SLC1A5. Also, both in vitro and in vivo methods of specifically detecting or/and measuring the level of ASCT1, and to the use of said polypeptides in diagnosis and therapy.
Absstract of: US20260201015A1
0000 Target-binding polypeptide are disclosed that include an amino acid sequence at least 50% identical to the amino acid sequence selected from the group consisting of SEQ ID NO:1-12, nucleic acids encoding such polypeptides, and methods for use of the polypeptides in detecting binding of the target and correlating binding to the target with a disease state.
Absstract of: US20260202406A1
0000 The present disclosure generally relates to compositions and methods for predicting or diagnosing immune-related adverse events (irAE) before, during, or after immune checkpoint inhibitor (ICI) treatment in a subject with cancer. The method includes assessment of abundance or expression of immune cells, autoantibodies, and/or cytokines.
Absstract of: WO2026149125A1
Provided are a nanobody against γ-aminobutyric acid type B receptor, and a preparation method therefor and the use thereof. The nanobody can specifically recognize and bind to the γ-aminobutyric acid type B receptor, exhibits a good affinity therefor, and can be used in the preparation of a product for diagnosing, preventing or treating diseases or conditions associated with the γ-aminobutyric acid type B receptor, or for detecting the presence or level of the γ-aminobutyric acid type B receptor in a sample.
Absstract of: US20260202422A1
The invention relates to a method of treatment for early onset preeclampsia in a pregnant subject, including determining a level of soluble fms-like tyrosine kinase-1 (sFlt-1) or fragment(s) thereof in a sample that has been isolated from said pregnant subject. The invention further relates to the combined measurement of sFlt-1 and PlGF, The invention relates further to a kit for carrying out the method of the invention, including detection reagents for determining the level sFlt-1 or fragment(s) thereof, and optionally for determining the level of at least one additional biomarker, in a sample from a subject.
Absstract of: US20260202427A1
0000 Described is use of biomarkers found in maternal mid-gestation (MMG) and cord blood (CB) plasma for early identification of children with autism spectrum disorder (ASD) or at risk for ASD. Using these biomarkers, newborns and infants with ASD or at high risk of ASD can be identified and interventions for ASD, which have been shown to be effective early in life, can be provided to a child as young as a newborn.
Absstract of: US20260201026A1
0000 The present invention relates to novel molecules that can be employed for the prevention, alleviation, treatment and/or diagnosis of diseases, disorders and abnormalities associated with alpha-synuclein (α-synuclein, A-synuclein, aSynuclein, A-syn, α-syn, aSyn, a-syn) aggregates, including, but not limited to, Lewy bodies and/or Lewy neurites, such as Parkinson's disease, Multiple System Atrophy, Lewy Body dementia (LBD; dementia with Lewy bodies (DLB) (“pure” Lewy body dementia), Parkinson's disease dementia (PDD)) or Diffuse Lewy Body Disease. The invention relates to alpha-synuclein binding molecules, in particular to alpha-synuclein antibodies or an antigen-binding fragment or a derivative thereof and uses thereof. The present molecules can also be used for determining a predisposition to such a disorder, disease or abnormality, monitoring residual disorder, disease or abnormality, or predicting the responsiveness of a patient who is suffering from such a disorder, disease or abnormality to treatment with a certain medicament.
Absstract of: WO2026151791A1
Provided herein are systems, kits, and methods for cell type-antigen marker (CTA marker) detection in cell samples (e.g., blood or CSF) from those suspected of having pre-clinical AD (Pre-AD) or mild cognitive impairment (MCI) or dementia from Alzheimer's Disease. In certain embodiments, such CTA marker detection is quantitative, gender specific, employs at least two gender-specific CTA markers in Figure 7C, and/or employs a mass cytometer (e.g., where mass-labeled antigen binding agents are mixed with the cell-sample). In some embodiments, at least some of the CTA markers are: i) unhealthy CTA markers which are generally upregulated in subjects with Pre-AD or MCI or dementia from Alzheimer's disease, and/or ii) healthy CTA markers which are generally down regulated in subjects with Pre-AD or MCI or Alzheimer's disease. In particular embodiments, the unhealthy CTA markers, and any healthy CTA markers employed, are used for determining a subject's risk of having or developing Pre-AD or MCI or dementia from Alzheimer's disease (e.g., by generating a score).
Absstract of: WO2026151983A1
Aspects of the disclosure relate to compositions and methods for modulating levels, transcription, splicing, and/or translation of one or more RNA transcripts (e.g., mRNA transcripts) in a cell or subject. The disclosure is based, in part, on methods of identifying a subject of having or being at risk of developing a disease or disorder associated with dysregulated glutamine levels, such as a subject having a mutation that affects glutaminase (GLS1), which is an enzyme responsible for producing glutamate from glutamine. In some embodiments, compositions and methods of the disclosure are useful for treating a psychiatric disorder (e.g., depression (DEP), major depressive disorder (MDD), bipolar disorder (e.g., BPD1, BPD2), mania (MAN), psychosis (PSY), schizophrenia (SCZ), schizoaffective disorder (SZA), or post-traumatic stress disorder (PTSD)) and/or a disease associated with dementia, such as Alzheimer's disease.
Absstract of: WO2026151932A1
The present disclosure relates to diagnosis, prognosis, and prediction of treatment outcomes of neuropathological conditions.
Absstract of: WO2026151876A1
Disclosed herein are embodiments related to analyzing brain-derived extracellular vesicles (EVs). Some methods described herein comprise: (a) enriching a biological sample for brain-derived EVs, the biological sample being from a subject having a brain-related condition or disorder and comprising the brain-derived EVs; (b) subjecting the enriched sample to EV disruption to produce an analytic sample; (c) purifying the analytic sample to capture EV material after the EV disruption; and (d) analyzing the captured EV material to determine a differential amount of the captured EV material relative to a control. The method allows for improving 10 outcomes for patients suffering from brain-related conditions or disorders.
Absstract of: WO2026150914A1
This pharmaceutical composition for use in the treatment of patients with diseases associated decreased ATP levels comprises the DNA or mRNA of at least one molecule selected from the group consisting of PI3Kα, IGFBP1, EIF2S2, OCIAD2, MANF, and GAPDHS.
Nº publicación: US20260199509A1 16/07/2026
Applicant:
ASTRAZENECA AB [SE]
ASTRAZENECA AB
Absstract of: US20260199509A1
Provided herein is a method of treating biliary tract cancers in humans. The method uses an antibody-drug conjugate (ADC) comprising an antibody (or antigen-binding fragment thereof) which specifically binds claudin 18.2 (CLDN18.2). The ADC is used for treatment of biliary tract cancers which express CLDN18.2.
BOPI
Electronic site
